StockNews.com Begins Coverage on Evoke Pharma (NASDAQ:EVOK)

Investment analysts at StockNews.com assumed coverage on shares of Evoke Pharma (NASDAQ:EVOK) in a research note issued on Wednesday. The firm set a “sell” rating on the specialty pharmaceutical company’s stock.

Evoke Pharma Stock Performance

Evoke Pharma stock opened at $3.85 on Wednesday. The firm has a market capitalization of $5.72 million, a PE ratio of -0.35 and a beta of 0.12. Evoke Pharma has a one year low of $3.44 and a one year high of $12.32. The stock’s 50 day moving average price is $4.55 and its 200 day moving average price is $4.72.

Evoke Pharma (NASDAQ:EVOK) last posted its quarterly earnings data on Thursday, March 13th. The specialty pharmaceutical company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.24). Evoke Pharma had a negative net margin of 71.32% and a negative return on equity of 308.49%.

Institutional Investors Weigh In On Evoke Pharma

A hedge fund recently bought a new stake in Evoke Pharma stock. Corsair Capital Management L.P. bought a new position in shares of Evoke Pharma, Inc. (NASDAQ:EVOK) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 11,667 shares of the specialty pharmaceutical company’s stock, valued at approximately $56,000. Corsair Capital Management L.P. owned 1.42% of Evoke Pharma as of its most recent filing with the Securities and Exchange Commission (SEC).

About Evoke Pharma

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.